Related Experiment Video

Updated: Feb 18, 2026

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines
07:49

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

3.2K

Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade

Hui-Wen Lue1, Jennifer Podolak1, Kevin Kolahi2

  • 1Knight Comprehensive Cancer Institute, Oregon Health and Science University, Portland, Oregon 97239, USA.

Genes & Development
|November 16, 2017
PubMed

Insights

Cancer therapies trigger autophagy, a process supplying nutrients for cell survival. Inhibiting phospholipase A2 (PLA2) alongside therapy can overcome this resistance by blocking nutrient supply and promoting apoptosis.

Area of Science:

  • Cancer Biology
  • Metabolic Pathways
  • Cellular Respiration

Background:

  • Limited understanding of metabolic reprogramming in cancer therapy resistance.
  • Cancer cells adapt metabolically to survive treatment.
  • PI3K-AKT-mTOR signaling inhibition impacts cancer cell metabolism.

Purpose of the Study:

  • Investigate metabolic reprogramming and autophagy in response to PI3K-AKT-mTOR inhibition.
  • Elucidate the role of phospholipase A2 (PLA2) in cancer cell survival.
  • Identify novel cotreatment strategies to overcome therapeutic resistance.

Main Methods:

  • Inhibition of PI3K-AKT-mTOR signaling pathway.
  • Analysis of cellular metabolism, including glycolysis and oxidative phosphorylation.
  • Assessment of autophagy induction and its role in nutrient supply.
  • Investigation of lipid droplet accumulation and mobilization.
  • Gene silencing of ATG5 and inhibition of PLA2.

Main Results:

  • PI3K-AKT-mTOR inhibition decreased glycolysis but induced autophagy.
  • Autophagy supplied metabolites for mitochondrial respiration and redox homeostasis.
  • Cancer cell survival depended on PLA2-mediated mobilization of lipids for fatty acid oxidation.
  • Inhibition of PLA2 reduced lipid droplets, oxidative phosphorylation, and increased apoptosis.

Conclusions:

  • Treatment-induced autophagy provides essential nutrients for cancer cell survival.
  • PLA2 is critical for mobilizing lipids to sustain mitochondrial respiration.
  • Targeting PLA2 in combination with PI3K-AKT-mTOR inhibitors offers a strategy to overcome therapeutic resistance.
Keywords:
autophagycancermetabolismphospholipidresistancesignaling

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.5K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K